Evidence map›Paper›PMID 22945331›Full record

ArticleNMR in biomedicine2013

Combined MR, fluorescence and histology imaging strategy in a human breast tumor xenograft model.

Lu Jiang, Tiffany R Greenwood, Erika R Amstalden van Hove, Kamila Chughtai, Venu Raman, Paul T Winnard, Ron M A Heeren, Dmitri Artemov, Kristine Glunde

Open access · greenAbstract read
In one paragraph

Article in NMR in biomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Magnetic Resonance Spectroscopy Studies of Mouse Models of Cancer.Methods in molecular biology (Clifton, N.J.) · 2018
    Article
  3. Review of quantitative multiscale imaging of breast cancer.Journal of medical imaging (Bellingham, Wash.) · 2018
    Review
  4. Article
  5. Article
  6. Mass spectrometric imaging of red fluorescent protein in breast tumor xenografts.Journal of the American Society for Mass Spectrometry · 2013
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Lu JiangThe Johns Hopkins University In Vivo Cellular and Molecular Imaging Center, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tiffany R Greenwood
Erika R Amstalden van Hove
Kamila Chughtai
Venu Raman
Paul T Winnard
Ron M A Heeren
Dmitri Artemov
Kristine Glunde
Imaging Center · USInstitute for Atomic and Molecular Physics · NLJohns Hopkins Medicine · USJohns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
Multi-scale Molecular Imaging of the Degradome in Breast TumorsR01CA154725 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE · 2011 to 2015
$1.7M
Imaging hypoxia-driven signaling pathways in the breast tumor microenvironmentR01CA134695 · NCI · JOHNS HOPKINS UNIVERSITY · PI GLUNDE, KRISTINE · 2008 to 2012
$1.5M
NCI NIH HHS P50 CA103175NCI NIH HHS R01 CA134695NCI NIH HHS R01 CA154725
6 · The paper itself

Abstract

Applications of molecular imaging in cancer and other diseases frequently require the combination of in vivo imaging modalities, such as MR and optical imaging, with ex vivo optical, fluorescence, histology and immunohistochemical imaging to investigate and relate molecular and biological processes to imaging parameters within the same region of interest. We have developed a multimodal image reconstruction and fusion framework that accurately combines in vivo MRI and MRSI, ex vivo brightfield and fluorescence microscopic imaging and ex vivo histology imaging. Ex vivo brightfield microscopic imaging was used as an intermediate modality to facilitate the ultimate link between ex vivo histology and in vivo MRI/MRSI. Tissue sectioning necessary for optical and histology imaging required the generation of a three-dimensional reconstruction module for two-dimensional ex vivo optical and histology imaging data. We developed an external fiducial marker-based three-dimensional reconstruction method, which was able to fuse optical brightfield and fluorescence with histology imaging data. The registration of the three-dimensional tumor shape was pursued to combine in vivo MRI/MRSI and ex vivo optical brightfield and fluorescence imaging data. This registration strategy was applied to in vivo MRI/MRSI, ex vivo optical brightfield/fluorescence and histology imaging datasets obtained from human breast tumor models. Three-dimensional human breast tumor datasets were successfully reconstructed and fused with this platform.

Indexed as

AnimalsBiomarkers, TumorBiopsyBreast NeoplasmsCell Line, TumorDisease Models, AnimalFemaleHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMiceMice, NudeMicroscopy, FluorescenceReproducibility of ResultsSensitivity and SpecificitySubtraction TechniqueBiomarkers, Tumor

Identifiers

PMID22945331
PMCPMC4162316
OpenAlexW2160362118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.